MLTX
MoonLake Immunotherapeutics
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-34/100
Last price
10.95
▼ 0.43 (3.78%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
11.38
Day high
11.50
Day low
10.91
Volume
3.05M
Market cap
$931.92M
P/E (TTM)
—
52W range
8.80 – 23.29
Trailing performance
Returnvs SPY
1W
-4.37%
-6.3%
1M
-27.05%
-28.2%
3M
-42.58%
-47.1%
6M
-35.89%
-54.1%
YTD
-16.92%
-31.2%
1Y
+29.89%
+13.5%
3Y
-80.79%
-163.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on MLTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
6.96M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 27, 26 | REICH KRISTIAN Officer |
SELL | 1.10K | $22.00K | Indirect |
| Jul 22, 26 | REICH KRISTIAN Officer |
SELL | 52.45K | $1.05M | Indirect |
| Jul 20, 26 | REICH KRISTIAN Officer |
SELL | 43.70K | $877.93K | Indirect |
| Jul 15, 26 | REICH KRISTIAN Officer |
SELL | 16.11K | $322.26K | Indirect |
| Jul 10, 26 | SANTOS DA SILVA JORGE Chief Executive Officer |
SELL | 102.22K | $2.05M | Direct |
| Jul 1, 26 | SANTOS DA SILVA JORGE Chief Executive Officer |
SELL | 47.77K | $956.93K | Direct |
| Jun 22, 26 | BODENSTEDT MATTHIAS Chief Financial Officer |
SELL | 39.12K | $862.21K | Direct |
| Jun 18, 26 | BODENSTEDT MATTHIAS Chief Financial Officer |
SELL | 17.88K | $351.58K | Direct |
| Jun 17, 26 | REICH KRISTIAN Officer |
SELL | 150.00K | $2.85M | Indirect |
| May 11, 26 | BODENSTEDT MATTHIAS Chief Financial Officer |
SELL | 13.65K | $273.33K | Direct |
| Apr 14, 26 | BODENSTEDT MATTHIAS Chief Financial Officer |
SELL | 2.43K | $47.45K | Direct |
| Apr 13, 26 | SANTOS DA SILVA JORGE Chief Executive Officer |
SELL | 150.00K | $2.75M | Direct |
| Apr 10, 26 | BODENSTEDT MATTHIAS Chief Financial Officer |
SELL | 87.80K | $1.66M | Direct |
| Mar 31, 26 | BVF PARTNERS L P Beneficial Owner of more than 10% of a Class of Security |
SELL | 3.75M | $62.96M | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BODENSTEDT MATTHIAS |
Chief Financial Officer | 1.12M | Sale |
BVF PARTNERS L P |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
CHEN BIHUA X. |
Former | — | Sale |
MOUKHEIBIR CATHERINE |
Director | 0 | Conversion of Exercise of derivative security |
REICH KRISTIAN |
Officer | — | Sale |
SANTOS DA SILVA JORGE |
Chief Executive Officer | 2.77M | Sale |
Fundamentals
Market cap$931.92M
Enterprise value$496.42M
Revenue (TTM)—
Gross profit—
EBITDA$-265.10M
Net income$-263.67M
EPS (TTM)$-3.83
Free cash flow$-131.86M
Total cash$537.03M
Total debt$101.53M
Book value / share$5.12
Shares outstanding85.11M
Float55.47M
Short % of float14.49%
Dividend yield0.00%
Beta (5Y)1.08
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.29
PEG ratio—
Price / sales—
Price / book2.14
EV / revenue—
EV / EBITDA-1.87
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-67.47%
Return on assets-32.44%
Debt / equity23.71
Current ratio12.56
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $202.86M | $112.77M | $31.80M | $42.05M | +79.9% |
| Selling, general & admin | $41.97M | $30.32M | $22.32M | $23.01M | +38.4% |
| Total operating expense | $244.83M | $143.09M | $54.12M | $65.06M | +71.1% |
| Operating income | -$244.83M | -$143.09M | -$54.12M | -$65.06M | -71.1% |
| Net interest income | -$7.25M | $0 | $0 | — | — |
| Pre-tax income | -$229.71M | -$120.96M | -$43.98M | -$64.47M | -89.9% |
| Tax provision | $611.00K | $282.00K | $94.00K | $36.37K | +116.7% |
| Net income | -$227.32M | -$118.94M | -$36.01M | -$49.97M | -91.1% |
| Net income to common | -$227.32M | -$118.94M | -$36.01M | -$49.97M | -91.1% |
| Basic EPS | -3.53 | -1.89 | -0.73 | -1.28 | -86.8% |
| Diluted EPS | -3.53 | -1.89 | -0.73 | -1.28 | -86.8% |
| EBIT | -$222.46M | -$120.96M | -$43.98M | -$65.06M | -83.9% |
| EBITDA | -$219.85M | -$119.58M | -$43.62M | -$64.90M | -83.9% |
| Basic shares | 64.46M | 62.87M | 49.12M | 38.98M | +2.5% |
| Diluted shares | 64.46M | 62.87M | 49.12M | 38.98M | +2.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $334.52M | $180.43M | $451.17M | $39.51M | — | +85.4% |
| Cash & short-term investments | $393.97M | $448.03M | $511.01M | $72.11M | — | -12.1% |
| Total current assets | $421.69M | $474.29M | $514.17M | $76.51M | — | -11.1% |
| Property, plant & equipment | $2.14M | $3.64M | $3.95M | $331.97K | — | -41.2% |
| Total assets | $424.43M | $477.93M | $526.54M | $76.84M | — | -11.2% |
| Total current liabilities | $45.48M | $22.46M | $9.97M | $7.67M | — | +102.5% |
| Current debt | — | — | — | — | $15.00M | — |
| Long-term debt | $74.10M | — | — | — | — | — |
| Total debt | $75.71M | $2.83M | $3.70M | $282.58K | — | +2,575.2% |
| Total liabilities | $119.95M | $24.54M | $13.05M | $8.08M | — | +388.8% |
| Retained earnings | -$462.91M | -$235.59M | -$116.66M | -$80.65M | — | -96.5% |
| Shareholder equity | $304.48M | $446.82M | $495.68M | $48.90M | — | -31.9% |
| Working capital | $376.22M | $451.83M | $504.20M | $68.85M | — | -16.7% |
| Net tangible assets | $304.48M | $446.82M | $495.68M | $48.90M | — | -31.9% |
| Shares issued | 71.37M | 63.08M | 60.47M | 38.98M | — | +13.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$230.32M | -$121.24M | -$44.08M | -$64.51M | -90.0% |
| Depreciation & amortisation | $2.62M | $1.39M | $370.00K | $164.78K | +88.9% |
| Stock-based compensation | $12.90M | $7.28M | $7.11M | $9.65M | +77.1% |
| Change in working capital | $19.88M | -$3.78M | -$6.22M | -$1.58M | +625.3% |
| Operating cash flow | -$196.01M | -$116.59M | -$42.78M | -$55.89M | -68.1% |
| Capital expenditure | -$35.00K | -$520.00K | -$284.00K | -$16.01K | +93.3% |
| Investing cash flow | $202.99M | -$205.60M | -$25.18M | -$32.34M | +198.7% |
| Share buybacks | — | -$50 | $0 | $0 | — |
| Financing cash flow | $146.00M | $51.31M | $479.70M | $119.69M | +184.5% |
| Free cash flow | -$196.04M | -$117.11M | -$43.06M | -$55.91M | -67.4% |
| End cash position | $334.52M | $180.43M | $451.17M | $39.51M | +85.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $50.22M | $54.52M | $56.01M | $60.63M | $49.76M | — | -7.9% |
| Selling, general & admin | $11.44M | $15.51M | $9.21M | $10.80M | $10.94M | — | -26.2% |
| Total operating expense | $61.66M | $70.02M | $65.22M | $71.43M | $60.70M | — | -11.9% |
| Operating income | -$61.66M | -$70.02M | -$65.22M | -$71.43M | -$60.70M | — | +11.9% |
| Net interest income | -$2.63M | -$2.27M | -$1.99M | -$3.20M | -$2.04M | — | -16.0% |
| Pre-tax income | -$61.72M | -$69.08M | -$62.77M | -$70.58M | -$55.96M | — | +10.7% |
| Tax provision | $90.00K | $622.00K | $248.00K | $115.00K | $95.00K | — | -85.5% |
| Net income | -$61.80M | -$69.71M | -$62.43M | -$69.73M | -$55.22M | — | +11.3% |
| Net income to common | -$61.80M | -$69.71M | -$62.43M | -$69.73M | -$55.22M | — | +11.3% |
| Basic EPS | -0.84 | -0.98 | — | -1.10 | -0.87 | -0.63 | +14.3% |
| Diluted EPS | -0.84 | -0.98 | — | -1.10 | -0.87 | -0.63 | +14.3% |
| EBIT | -$59.08M | -$66.82M | -$60.78M | -$67.38M | -$53.92M | — | +11.6% |
| EBITDA | -$58.19M | -$65.97M | -$60.02M | -$66.64M | -$53.18M | — | +11.8% |
| Basic shares | 73.92M | 71.27M | — | 63.37M | 63.28M | 63.23M | +3.7% |
| Diluted shares | 73.92M | 71.27M | — | 63.37M | 63.28M | 63.23M | +3.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $477.90M | $298.49M | $334.52M | $350.74M | $306.68M | +60.1% |
| Cash & short-term investments | $537.03M | $357.92M | $393.97M | $380.48M | $425.08M | +50.0% |
| Total current assets | $570.04M | $396.64M | $421.69M | $411.21M | $455.48M | +43.7% |
| Property, plant & equipment | $2.56M | $2.39M | $2.14M | $2.53M | $2.92M | +7.4% |
| Total assets | $573.95M | $400.37M | $424.43M | $414.33M | $460.10M | +43.4% |
| Total current liabilities | $45.39M | $46.11M | $45.48M | $48.37M | $27.36M | -1.6% |
| Long-term debt | $99.51M | $99.02M | $74.10M | $73.74M | $73.38M | +0.5% |
| Total debt | $101.53M | $100.80M | $75.71M | $75.73M | $75.77M | +0.7% |
| Total liabilities | $145.75M | $146.35M | $119.95M | $123.14M | $102.15M | -0.4% |
| Retained earnings | -$594.42M | -$532.62M | -$462.91M | -$400.49M | -$330.76M | -11.6% |
| Shareholder equity | $428.19M | $254.02M | $304.48M | $288.91M | $353.73M | +68.6% |
| Working capital | $524.65M | $350.53M | $376.22M | $362.85M | $428.12M | +49.7% |
| Net tangible assets | $428.19M | $254.02M | $304.48M | $288.91M | $353.73M | +68.6% |
| Shares issued | 83.61M | 72.13M | 71.37M | 63.70M | 63.47M | +15.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$61.81M | -$69.71M | -$63.02M | -$70.69M | -$56.05M | — | +11.3% |
| Depreciation & amortisation | $896.00K | $845.00K | $751.00K | $745.00K | $742.00K | — | +6.0% |
| Stock-based compensation | $2.55M | $13.36M | $3.59M | $3.71M | $3.31M | — | -80.9% |
| Change in working capital | $2.78M | -$11.21M | $6.00K | $21.43M | -$1.19M | — | +124.8% |
| Operating cash flow | -$55.56M | -$66.29M | -$58.79M | -$44.54M | -$54.53M | — | +16.2% |
| Capital expenditure | — | — | — | — | — | -$35.00K | — |
| Investing cash flow | $322.00K | $98.00K | -$29.91M | $88.40M | $88.25M | — | +228.6% |
| Financing cash flow | $234.62M | $30.64M | $72.39M | $480.00K | $0 | — | +665.6% |
| Free cash flow | -$55.56M | -$66.29M | -$58.79M | -$44.54M | -$54.53M | — | +16.2% |
| End cash position | $477.90M | $298.49M | $334.52M | $350.74M | $306.68M | — | +60.1% |
Options analytics
Put / call volume
0.17
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
10.00
-8.7% from spot
ATM implied vol
1.6%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
553
Contracts, this expiry
Put volume
96
Contracts, this expiry
Heaviest call OI
11.00
0 contracts
Heaviest put OI
10.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.90 | -0.84 | +6.2% |
| Mar 2026 | -0.92 | -0.98 | -6.4% |
| Dec 2025 | -0.94 | -0.92 | +2.6% |
| Sep 2025 | -0.92 | -1.10 | -20.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.78 | 7 | $0 | 0.0% |
| Next quarter | -0.81 | 7 | $0 | 0.0% |
| Current year | -3.38 | 7 | $0 | 0.0% |
| Next year | -3.33 | 9 | $19.04M | 0.0% |
Analyst targets & ownership
Mean target$28.54
High target$50.00
Low target$6.00
Implied upside160.63%
Analyst count13
ConsensusBUY
Strong buy / Buy1 / 10
Hold2
Sell / Strong sell2 / 0
Held by insiders8.18%
Held by institutions87.83%
Institutions holding220
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.70
-6.39% from price
SMA 20
12.22
-10.39% from price
SMA 50
14.81
-26.09% from price
SMA 100
16.89
-35.15% from price
SMA 200
16.74
-34.57% from price
EMA 12
11.82
-7.40% from price
EMA 26
12.86
-14.86% from price
EMA 50
14.29
-23.39% from price
RSI (14)
25.8
Oversold
MACD (12,26,9)
-1.04
Hist 0.02
ATR (14)
0.63
5.71% of price
Realised vol 30D
46.2%
Annualised
Bollinger upper
13.66
20, 2σ
Bollinger lower
10.78
20, 2σ
50 / 200 cross
Death
14.81 vs 16.74
Trend bias
Below 200
-34.57%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.19
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
46.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-50.6%
Peak to trough
Max drawdown 5Y
-90.2%
Peak to trough
ATR 14
0.63
5.71% of price
Beta (reported)
1.08
5Y monthly, from filing
Short interest
Shares short
8.95M
Prior 6.82M
Change vs prior
+31.2%
Shorts adding
% of float
14.49%
Elevated
% of shares out
10.51%
Against total outstanding
Days to cover
7.0
Crowded exit
Float
55.47M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 1, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Jun 9, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 8, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 12, 26 | Needham | MAINTAINED | Buy | Buy |
| May 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 30, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 23, 26 | Wolfe Research | UPGRADE | Underperform | Outperform |
| Mar 19, 26 | Rothschild & Co | UPGRADE | Neutral | Buy |
| Mar 11, 26 | Clear Street | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-30
Periodic Financial Reports
10-Q · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-07-15
Corporate Changes & Voting Matters
8-K · 2026-06-25
Corporate Changes & Voting Matters
8-K · 2026-06-09
Corporate Changes & Voting Matters
8-K · 2026-06-01
Periodic Financial Reports
10-Q · 2026-05-11
Proxy Statements
DEF 14A · 2026-04-21
Headlines
MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
MT Newswires · 2d ago
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
GlobeNewswire · 16d ago
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
Stocktwits · 26d ago
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’
Stocktwits · 58d ago
MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals
MT Newswires · 58d ago
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
Stocktwits · 65d ago
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
Zacks · 68d ago
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
Zacks · 68d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.